Affinity maturation of antiHER2 monoclonal antibody MIL5 using an epitope-specific synthetic phage library by computational design

Journal of Biomolecular Structure and Dynamics

Volumn 31, Issue 5, 2013, Pages 511-521

  Qiao, Chunxial ^a   Lv, Mingl ^a   Li, Xinying ^a   Geng, Jing ^a   Li, Yan ^a   Zhang, Jiyan ^a   Lin, Zhou ^a   Feng, Jiannan ^a   Shen, Beifen ^a  

^a INSTITUTE OF BASIC MEDICAL SCIENCES   (China)

Author keywords

Affinity maturation; Epitope specific phage library; HER2 ErbB2 antibody

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPITOPE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY MIL5; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG SCREENING; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MUTANT; NONHUMAN; OVARY CARCINOMA; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; SITE DIRECTED MUTAGENESIS; TUMOR VOLUME; TUMOR XENOGRAFT;

AMINO ACID MOTIFS; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; COMPUTER SIMULATION; DRUG DESIGN; EPITOPE MAPPING; EPITOPES; FEMALE; HEK293 CELLS; HUMANS; MICE; MICE, NUDE; MODELS, MOLECULAR; OVARIAN NEOPLASMS; PEPTIDE LIBRARY; PROTEIN BINDING; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN STRUCTURE, SECONDARY; RECEPTOR, ERBB-2; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84879202366     PISSN: 07391102     EISSN: 15380254     Source Type: Journal    
DOI: 10.1080/07391102.2012.706073     Document Type: Article

References (47)

1. Adams, C.W., Allison, D.E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., ...Sliwkowski, M.X. (2006). Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunology, Immunotherapy, 55(6), 717-727.
2. Arteaga, C.L. (2003). Trastuzumab, an appropriate first-line single- agent therapy for HER2-overexpressing metastatic breast cancer. Breast Cancer Research, 5(2), 96-100.
3. Azzazy, H.M., & Highsmith, W.E.Jr. (2002). Phage display technology: Clinical applications and recent innovations. Clinical Biochemistry, 35(6), 425-445.
4. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T. N., Weissig, H., ...Bourne, P.E. (2000). The Protein Data Bank. Nucleic Acids Research, 28(1), 235-242.
5. Blaise, L., Wehnert, A., Steukers, M.P., van den Beucken, T., Hoogenboom, H.R., & Hufton, S.E. (2004). Construction and diversification of yeast cell surface displayed libraries by yeast mating: Application to the affinity maturation of Fab antibody fragments. Gene, 342(2), 211-218.
6. Chames, P., Hufton, S.E., Coulie, P.G., Uchanska-Ziegler, B., & Hoogenboom, H.R. (2000). Direct selection of a human antibody fragment directed against the tumor T-cell epitope HLA-A1-MAGE-A1 from a nonimmunized phage-Fab library. Proceedings of the National Academy of Sciences USA, 97(14), 7969-7974.
7. Cho, H.S., Mason, K., Ramyar, K.X., Stanley, A.M., Gabelli, S.B., & Denney, D.W.Jr. (2003). Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature, 421(6924), 756-760.
8. Cobleigh, M.A., Vogel, C.L., Tripathy, D., Robert, N.J., Scholl, S., Fehrenbacher, L., ...Slamon, D.J. (1999). Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. Journal Clinical Oncology, 17(9), 2639-2648.
9. Connolly, S.J., Kates, R.E., Lebsack, C.S., Echt, D.S., Mason, J.W., & Winkle, R.A. (1983). Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. American Journal of Cardiology, 52(10), 1208-1213.
10. de Haard, H.J., van Neer, N., Reurs, A., Hufton, S.E., Roovers, R.C., Henderikx, P., ...Hoogenboom, H.R. (1999). A large non-immunized human Fab fragment phage library that permits rapid isolation and kinetic analysis of high affinity antibodies. Journal of Biological Chemistry, 274(26), 18218-18230.
11. Franklin, M.C., Carey, K.D., Vajdos, F.F., Leahy, D.J., de Vos, A.M., & Sliwkowski, M.X. (2004). Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell, 5(4), 317-328.
12. Graff, C.P., Chester, K., Begent, R., & Wittrup, K.D. (2004). Directed evolution of an anti-carcinoembryonic antigen scFv with a 4-day monovalent dissociation half-time at 37 degrees C. Protein Engineering, Design & Selection, 17(4), 293-304.
13. Griffiths, A.D., Williams, S.C., Hartley, O., Tomlinson, I.M., Waterhouse, P., Crosby, W.L., ...Winter, G. (1994). Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO Journal, 13(14), 3245-3260.
14. Hanes, J., Jermutus, L., Weber-Bornhauser, S., Bosshard, H.R., & Pluckthun, A. (1998). Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proceedings of the National Academy of Sciences USA, 95(24), 14130-14135.
15. Harvey, B.R., Georgiou, G., Hayhurst, A., Jeong, K.J., Iverson, B.L., & Rogers, G.K. (2004). Anchored periplasmic expression, a versatile technology for the isolation of high-affinity antibodies from Escherichia coli-expressed libraries. Proceedings of the National Academy of Sciences USA, 101 (25), 9193-9198.
16. Ho, M., Kreitman, R.J., Onda, M., & Pastan, I. (2005). In vitro antibody evolution targeting germline hot spots to increase activity of an anti-CD22 immunotoxin. Journal of Biological Chemistry, 280(1), 607-617.
17. Hoet, R.M., Cohen, E.H., Kent, R.B., Rookey, K., Schoonbroodt, S., Hogan, S., ...Ladner, R.C. (2005). Generation of high-affinity human antibodies by combining donorderived and synthetic complementarity-determining-region diversity. Nature Biotechnology, 23(3), 344-348.
18. Holbro, T., Civenni, G., & Hynes, N.E. (2003). The ErbB receptors and their role in cancer progression. Experimental Cell Research, 284(1), 99-110.
19. Hoogenboom, H.R. (2002). Overview of antibody phage-display technology and its applications. Methods in Molecular Biology, 178, 1-37.
20. Hoogenboom, H.R. (2005). Selecting and screening recombinant antibody libraries. Nature Biotechnology, 23(9), 1105-1116.
21. Huie, M.A., Cheung, M.C., Muench, M.O., Becerril, B., Kan, Y.W., & Marks, J.D. (2001). Antibodies to human fetal erythroid cells from a nonimmune phage antibody library. Proceedings of the National Academy of Sciences USA, 98(5), 2682-2687.
22. Knappik, A., Ge, L., Honegger, A., Pack, P., Fischer, M., Wellnhofer, G., ...Virnekas, B. (2000). Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs randomized with trinucleotides. Journal of Molecular Biology, 296(1), 57-86.
23. Kramer, R.A., Marissen, W.E., Goudsmit, J., Visser, T.J., Clijsters-Van der Horst, M., Bakker, A.Q., ...de Kruif, J. (2005). The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries. European Journal of Immunology, 35(7), 2131-2145.
24. Kuntz, E.F. (1982). Digital imaging makes rapid gains. Mod Healthc, 12(1), 74, 76.
25. Lorenz, H.M. (2002). Technology evaluation: Adalimumab, Abbott laboratories. Current Opinion in Molecular Therapeutics, 4(2), 185-190.
26. Lu, D., Shen, J., Vil, M.D., Zhang, H., Jimenez, X., Bohlen, P., ...Zhu, Z. (2003). Tailoring in vitro selection for a picomolar affinity human antibody directed against vascular endothelial growth factor receptor 2 for enhanced neutralizing activity. Journal of Biological Chemistry, 278 (44), 43496-43507.
27. Moulard, M., Phogat, S.K., Shu, Y., Labrijn, A.F., Xiao, X., Binley, J.M., ...Dimitrov, D.S. (2002). Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proceedings of the National Academy of Sciences USA, 99(10), 6913-6918.
28. Mullen, L.M., Nair, S.P., Ward, J.M., Rycroft, A.N., & Henderson, B. (2006). Phage display in the study of infectious diseases. Trends in Microbiology, 14(3), 141-147.
29. Paik, S., & Liu, E.T. (2000). HER2 as a predictor of therapeutic response in breast cancer. Breast Disease, 11, 91-102.
30. Pantazes, R.J., & Maranas, C.D. (2010). OptCDR: A general computational method for the design of antibody complementarity determining regions for targeted epitope binding. Protein Engineering, Design & Selection, 23(11), 849-858.
31. Pini, A., Viti, F., Santucci, A., Carnemolla, B., Zardi, L., Neri, P., ...Neri, D. (1998). Design and use of a phage display library. Human antibodies with subnanomolar affinity against a marker of angiogenesis eluted from a twodimensional gel. Journal of Biological Chemistry, 273(34), 21769-21776.
32. Qiao, Y.Y., Chen, X.S., Wang, Y.X., & Hua, B. (2004). Construction of a large single-chain phage antibody library. Chinese Journal of Microbiology and Immunology, 24(3), 4.
33. Ross, J.S., & Fletcher, J.A. (1998). The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells, 16(6), 413-428.
34. Sakamoto, G., & Mitsuyama, S. (2000). New molecule-targeting therapy with herceptin (trastuzumab), an anti-HER2 (c-erB-2) monoclonal antibody. Breast Cancer, 7(4), 350-357.
35. Schier, R., McCall, A., Adams, G.P., Marshall, K.W., Merritt, H., Yim, M., ...Marks, J.D. (1996). Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. Journal of Molecular Biology, 263(4), 551-567.
36. Shoichet, B.K., & Kuntz, I.D. (1991). Protein docking and complementarity. Journal of Molecular Biology, 221(1), 327-346.
37. Shoichet, B.K., & Kuntz, I.D. (1993). Matching chemistry and shape in molecular docking. Protein Engineering, 6(7), 723-732.
38. Slamon, D.J., Clark, G.M., Wong, S.G., Levin, W.J., Ullrich, A., & McGuire, W.L. (1987). Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science, 235(4785), 177-182.
39. Slamon, D., & Pegram, M. (2001). Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. Seminars in Oncology, 28(1 Suppl 3), 13-19.
40. Smith, G.P. (1985). Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 228(4705), 1315-1317.
41. Swers, J.S., Kellogg, B.A., & Wittrup, K.D. (2004). Shuffled antibody libraries created by in vivo homologous recombination and yeast surface display. Nucleic Acids Research, 32(3), e36.
42. van den Beucken, T., Pieters, H., Steukers, M., van der Vaart, M., Ladner, R.C., Hoogenboom, H.R., ...Hufton, S.E. (2003). Affinity maturation of Fab antibody fragments by fluorescent-activated cell sorting of yeast-displayed libraries. FEBS Letter, 546(2-3), 288-294.
43. Vaughan, T.J., Williams, A.J., Pritchard, K., Osbourn, J.K., Pope, A.R., Earnshaw, J.C., ...Johnson, K.S. (1996). Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nature Biotechnology, 14(3), 309-314.
44. Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., ...Press, M. (2002). Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. Journal Clinical Oncology, 20(3), 719-726.
45. Winter, G., & Milstein, C. (1991). Man-made antibodies. Nature, 349(6307), 293-299.
46. Wu, H., Beuerlein, G., Nie, Y., Smith, H., Lee, B.A., Hensler, M., ...Watkins, J.D. (1998). Stepwise in vitro affinity maturation of Vitaxin, an alphav beta3-specific humanized mAb. Proceedings of the National Academy of Sciences USA, 95(11), 6037-6042.
47. Yang, W.P., Green, K., Pinz-Sweeney, S., Briones, A.T., Burton, D.R., & Barbas, C.F., 3rd. (1995). CDR walking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. Journal of Molecular Biology, 254(3), 392-403.